We serve Chemical Name:7,8-difluoro-4-methyl-2H-isoquinolin-1-one CAS:1269294-33-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:7,8-difluoro-4-methyl-2H-isoquinolin-1-one
CAS.NO:1269294-33-8
Synonyms:s14-1830;s14-1939
Molecular Formula:C10H7F2NO
Molecular Weight:195.16500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:33.12000
Exact Mass:195.05000
LogP:2.52700
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like s14-1830 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,s14-1939 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,s14-1830 Use and application,s14-1939 technical grade,usp/ep/jp grade.
Related News: In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 7,8-difluoro-4-methyl-2H-isoquinolin-1-one manufacturer The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 7,8-difluoro-4-methyl-2H-isoquinolin-1-one supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. 7,8-difluoro-4-methyl-2H-isoquinolin-1-one vendor Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 7,8-difluoro-4-methyl-2H-isoquinolin-1-one factory Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.
